Lupus Therapeutics, the clinical trial affiliate of the Lupus Research Alliance, is starting a clinical study to assess the potential benefit of hydroxychloroquine and/or other lupus therapies in preventing or decreasing the symptoms of COVID-19 in people with lupus, it was reported on Tuesday.
The study will be designed and conducted in partnership with Lupus Therapeutics' Lupus Clinical Investigators Network, which includes 57 academic medical centres in the United States and Canada. Around 20,000 lupus patients are part of the network.
This study is intended to follow up on anecdotal data from several academic centres within the Lupus Clinical Investigators Network.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA